EN DE
Watch Vir Biotechnology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vir Biotechnology Inc (VIR) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Vir Biotechnology Inc stock $8.04, price $9.58, that is 16.1% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US92764N1028

VB Vir Biotechnology Inc logo Thin data Nov 17, 2026

Vir Biotechnology Inc

VIR · US

Expensive (fair value 16% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Profit last quarter +59% vs. a year ago. 
Mixed vs. peers (5/9) 
Recent news mixed 
Insiders sold $75,761 (6M) 
Fair value $8.04 · Overvalued 
Quality 38/100 
Weak Growth (revenue 5y −2.1 %/yr in USD) 
Loss-making · -61.0% net margin (TTM) 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Vir Biotechnology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$54.54 $4.28 Fair Value $8.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $4.28 – $54.54 · fair‑value band $6.03 – $10.05 · the $9.58 price screens above the $8.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Vir Biotechnology in your weekly email

Every Wednesday you see whether Vir Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Show moreShow less

Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.

It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Stock analysis

Vir Biotechnology Inc (VIR) currently trades at $9.58, while our estimate is $8.04, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $6.03 (bear) to $10.05 (bull), the price of $9.58 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Vir Biotechnology Inc reported revenue of $68.6M in FY2025 versus $1.1B in FY2021, a compound −50.0%/yr. Reported net income was −$438M in FY2025.

Key figures

Market cap $2.1B Mid · P/S ratio 6.91 · EPS (TTM) $−1.18 · Net margin −61.0% · Return on equity −21.8% · Return on assets (EBIT) −14.6% (5-year average) · Operating margin 55,669% · Revenue growth (YoY) +196%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and 76% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, VIR screens richer than that median.

Fair Value

Bear $6.03 Fair Value $8.04 Bull $10.05
Price $9.58 · Downside -16.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 2
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 75
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $75,761 and none bought.

  • SaleVanina de VerneuilEVP, General Counsel, Corp Sec3× since Feb 23, 2026: 25,012 shares, avg. $9.57$239,294Nov 3, 202610b5-1 plan
  • SaleBrent SabatiniSVP, Chief Accounting Officer5× since Feb 13, 2026: 12,879 shares, avg. $8.78$113,079Jun 1, 202610b5-1 plan
  • SaleJanet NapolitanoDirector3,200 shares at $9.45$30,240Jun 1, 202610b5-1 plan
  • SaleVicki L SatoDirector7× since Dec 1, 2025: 174,377 shares, avg. $8.46$1.5MMay 1, 202610b5-1 plan
  • SaleMarianne De BackerPresident and CEO, Director3× since Feb 23, 2026: 106,360 shares, avg. $8.91$947,163Apr 6, 202610b5-1 plan
  • SaleMark EisnerEVP and Chief Medical Officer2× since Feb 23, 2026: 5,594 shares, avg. $8.85$49,514Feb 25, 202610b5-1 plan
  • SaleJason O'ByrneEVP & Chief Financial Officer3× since Nov 17, 2025: 10,522 shares, avg. $6.55$68,938Feb 24, 202610b5-1 plan
  • SaleSVF Endurance (Cayman) Ltd10% owner2× since Nov 24, 2025: 655,628 shares, avg. $6.18$4.1MDec 1, 202510b5-1 plan
  • SaleSOFTBANK VISION FUND (AIV M1) L.P.10% owner189,431 shares at $6.41$1.2MNov 28, 202510b5-1 plan

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+115.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−388.9% (2020) → −682.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VIR screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (89 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Vir Biotechnology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −16.1% · Above median
Profitability
Return on assets −43.7% · Below median
Net margin (12 months) −61.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 195.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.73× · Pricier than median
P/S (12 months) 6.91× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs VIR
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs VIR
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs VIR
argenx SE ARGX $950.95 $908.40 −4% vs VIR
CSL Limited CSL A$199.55 A$186.49 −7% vs VIR
Moderna, Inc MRNA $215.27 $135.64 −37% vs VIR
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs VIR
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs VIR
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs VIR
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs VIR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vir Biotechnology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vir Biotechnology Inc Fair Value". https://www.fairvalue-calculator.com/stock/VIR

Frequently asked questions

Is Vir Biotechnology Inc (VIR) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $8.04 versus a price of $9.58, about 16% lower (overvalued).
What is the fair value of VIR?
Our estimate for Vir Biotechnology Inc is $8.04 (as of Nov 17, 2026), built from audited fundamentals. The current price: $9.58.
What is the quality score of VIR?
Vir Biotechnology Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vir Biotechnology Inc (VIR)?
Our calculated price target is the estimate of $8.04 (as of Nov 17, 2026). Cautious scenario $6.03, optimistic scenario $10.05. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vir Biotechnology Inc stock forecast for 2026?
Our estimate puts fair value at $8.04, about 16% lower versus a price of $9.58 (overvalued). Cautious scenario $6.03, optimistic scenario $10.05. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Vir Biotechnology Inc (VIR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vir Biotechnology Inc it is $8.04 per share (as of Nov 17, 2026), against a price of $9.58.
Is Vir Biotechnology Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, VIR trades above its calculated fair value: price $9.58, fair value $8.04, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIR?
No. The price is what the market pays today ($9.58); the fair value is what the company's own numbers justify ($8.04). For Vir Biotechnology Inc the two are $1.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vir Biotechnology Inc worth?
The market values Vir Biotechnology Inc at about $2.1B (market capitalisation, as of Nov 17, 2026). Per share that is $9.58; our models calculate a fair value of $8.04 per share.
What do the bullish and bearish scenarios say about VIR?
Our models span a range for Vir Biotechnology Inc: cautious scenario $6.03, base $8.04, optimistic $10.05 per share (as of Nov 17, 2026, price $9.58). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vir Biotechnology Inc (VIR)?
Balance-sheet figures for Vir Biotechnology Inc (as of Nov 17, 2026): return on equity −21.8%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is VIR from its 52-week high?
Vir Biotechnology Inc trades at $9.58, about 30% below its 52-week high of $13.65 and 76% above the low of $5.44 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $8.04 is for.
Which stocks are comparable to Vir Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vir Biotechnology Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $9.58, calculated fair value $8.04 (−16%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Vir Biotechnology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vir Biotechnology Inc (VIR)?
The closing price on Nov 16, 2026 was $9.58. Our estimate is $8.04, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vir Biotechnology Inc right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vir Biotechnology Inc

How large is the market capitalisation of Vir Biotechnology Inc (VIR)?
The market capitalisation of Vir Biotechnology Inc is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vir Biotechnology Inc (VIR)?
The price-to-sales ratio of Vir Biotechnology Inc is 6.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vir Biotechnology Inc (VIR)?
Earnings per share at Vir Biotechnology Inc are $−1.18. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vir Biotechnology Inc (VIR)?
The net margin of Vir Biotechnology Inc is −61.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vir Biotechnology Inc (VIR)?
The return on equity (ROE) of Vir Biotechnology Inc is −21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vir Biotechnology Inc (VIR)?
On an EBIT basis the return on assets of Vir Biotechnology Inc is −14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vir Biotechnology Inc (VIR)?
The operating margin of Vir Biotechnology Inc is 55,669% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vir Biotechnology Inc (VIR)?
Revenue at Vir Biotechnology Inc is growing 196% versus a year earlier (3y avg −65.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vir Biotechnology Inc (VIR)?
Earnings per share at Vir Biotechnology Inc are growing 58.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vir Biotechnology Inc (VIR) generate?
The free cash flow of Vir Biotechnology Inc is −$397M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Vir Biotechnology Inc (VIR) hold?
Vir Biotechnology Inc holds more cash than debt, $128M net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Vir Biotechnology Inc in the live analysis

One click puts Vir Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.